{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:05:10Z","timestamp":1779966310642,"version":"3.53.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12328-026-02300-9","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:22:25Z","timestamp":1774264945000},"page":"622-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of a patient with advanced HCC with Vp4 on hemodialysis who responded to a multimodality treatment including hepatic arterial infusion, radiation therapy, immunotherapy, and molecular-targeted drugs"],"prefix":"10.1007","volume":"19","author":[{"given":"Yumi","family":"Kosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"20","key":"2300_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"21","key":"2300_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215475","volume":"13","author":"M Kudo","year":"2021","unstructured":"Kudo M. Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy. Cancers (Basel). 2021;13(21):5475.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2300_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"key":"2300_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/JHC.S347932","volume":"10","author":"V Zanuso","year":"2023","unstructured":"Zanuso V, Pirozzi A, Balsano R, et al. Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1689\u2013708.","journal-title":"J Hepatocell Carcinoma"},{"key":"2300_CR5","first-page":"S0168","volume":"11","author":"R Lorenza","year":"2025","unstructured":"Lorenza R, Stephen LC, Bruno S, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;11:S0168-8278.","journal-title":"J Hepatol"},{"key":"2300_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052937","volume":"13","author":"F Xie","year":"2022","unstructured":"Xie F, Liu Z, Yang F, et al. Efficacy of immune checkpoint inhibitors plus molecular targeted agents in hepatocellular carcinoma. Front Immunol. 2022;13:105293.","journal-title":"Front Immunol"},{"key":"2300_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000513706","volume":"10","author":"Y Kosaka","year":"2021","unstructured":"Kosaka Y, Kimura T, Kawaoka T, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein. Liver Cancer. 2021;10:151\u201360.","journal-title":"Liver Cancer"},{"key":"2300_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/hepr.12392","volume":"45","author":"H Fujino","year":"2015","unstructured":"Fujino H, Kimura T, Aikata H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607\u201317.","journal-title":"Hepatol Res"},{"issue":"6","key":"2300_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterology & Hepatology. 2018;3(6):424\u201332.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"4","key":"2300_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000486483","volume":"94","author":"K Kodama","year":"2018","unstructured":"Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology. 2018;94(4):215\u201322.","journal-title":"Oncology"},{"key":"2300_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104735","volume":"211","author":"Y Xinyi","year":"2025","unstructured":"Xinyi Y, Xizhu F, Fangfang L, et al. Targeting TIME in advanced hepatocellular carcinoma: mechanisms of drug resistance and treatment strategies. Crit Rev Oncol Hematol. 2025;211:104735.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"2300_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896752","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Haoyue H, Yuan X, et al. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol. 2022;10(13):896752.","journal-title":"Front Immunol"},{"key":"2300_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107003","volume":"275","author":"J Jiang","year":"2025","unstructured":"Jiang J, Zhang H, Yanjiao O, et al. The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment. Immunol Lett. 2025;275:107003.","journal-title":"Immunol Lett"},{"issue":"2","key":"2300_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000531820","volume":"13","author":"M Ikeda","year":"2023","unstructured":"Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD. Liver Cancer. 2023;13(2):193\u2013202.","journal-title":"Liver Cancer"},{"issue":"7","key":"2300_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/hepr.14194","volume":"55","author":"T Terashima","year":"2025","unstructured":"Terashima T, Yamamoto M, Toyama T, et al. The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma. Hepatol Res. 2025;55(7):1026\u201337.","journal-title":"Hepatol Res"},{"key":"2300_CR16","unstructured":"Thomas Yau, Peter R Galle, Thomas Decaens, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025:S0140\u20136736(25)00403\u20139."},{"issue":"5","key":"2300_CR17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/ndt\/gfw077","volume":"32","author":"AC Shirali","year":"2017","unstructured":"Shirali AC, Pedrazzoli P, Janus N, et al. Management of chemotherapy including cisplatin in patients with end-stage renal disease on hemodialysis. Nephrol Dial Transplant. 2017;32(5):800\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"2300_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1412-8","volume":"38","author":"Z Liu","year":"2019","unstructured":"Liu Z, Lin Y, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447.","journal-title":"J Exp Clin Cancer Res"},{"key":"2300_CR19","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Huang A. Hepatocellular carcinoma: signaling pathways and systemic therapy progress. Signal Transduct Target Ther. 2025;10:75.","journal-title":"Signal Transduct Target Ther"},{"key":"2300_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-024-01246-9","volume":"25","author":"H Dong","year":"2024","unstructured":"Dong H, Xie F, et al. Combination of immunotherapy and targeted therapy in hepatocellular carcinoma. Curr Treat Options Oncol. 2024;25:12.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"2300_CR21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover SP, Hisada YM, Kasthuri RS, et al. Cancer Therapy-Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291\u2013305.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2300_CR22","doi-asserted-by":"crossref","unstructured":"Rhian M Touyz, Sandra MS Herrmann, Joerg Herrmann, et al. Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events. J Am Soc Hypertension, 2018;12(6):409\u2013425.","DOI":"10.1016\/j.jash.2018.03.008"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02300-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:22:49Z","timestamp":1779963769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02300-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}